Home Newsfeeds Cidara Therapeutics Q2 EPS $(0.19) Down From $0.18 YoY

Cidara Therapeutics Q2 EPS $(0.19) Down From $0.18 YoY

Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(0.19) per share. This is a 205.56 percent decrease over earnings of $0.18 per share from the same period last year.

byBenzinga Newsdesk

August 9, 2022

1 minute read

Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(0.19) per share. This is a 205.56 percent decrease over earnings of $0.18 per share from the same period last year.

$1000 Invested In This Stock 15 Years Ago Would Be Worth $2,800 Today

By Benzinga Insights

July 14, 5:00 PM

Johnson & Johnson (NYSE:JNJ) has outperformed the market over the past 15 years by 1.03% on an annualized basis producing an average annual return of 7.21%. Currently, Johnson & Johnson has a market capitalization of $462.23 billion.

JNJ

EOG Resources Q4 EPS $3.30 Misses $3.37 Estimate, Sales $6.72B Beat $6.62B Estimate

By Happy Mohamed

February 23, 5:33 PM

EOG Resources (NYSE:EOG) reported quarterly earnings of $3.30 per share which missed the analyst consensus estimate of $3.37 by 2.08 percent. This is a 6.8 percent increase over earnings of $3.09 per share from the same

EOG

Apellis Shares Climb As FDA Accepts Geographic Atrophy Candidate Submission Under Priority Review

By Ragothaman Srinivasan

July 19, 8:22 AM

The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation for Apellis Pharmaceuticals’ (NASDAQ: APLS) New Drug Application (NDA) for the intravitreal pegcetacoplan. The regulatory agency has assigned target action date of November 26, 2022.

APLS

Why Theriva Biologics Are Trading Higher By Over 76%; Here Are 20 Stocks Moving Premarket

By Lisa Levin

June 28, 8:04 AM

Gainers Theriva Biologics, Inc. (NYSE: TOVX) shares surged 76.4% to $1.46 in pre-market trading after the company said Orphan Drug Designation was granted by the U.S. Food and Drug Administration for VCN-01 for the treatment of pancreatic cancer.

AREB

Cidara Therapeutics Q2 EPS $(0.19) Down From $0.18 YoY

Related Posts

$1000 Invested In This Stock 15 Years Ago Would Be Worth $2,800 Today

EOG Resources Q4 EPS $3.30 Misses $3.37 Estimate, Sales $6.72B Beat $6.62B Estimate

Apellis Shares Climb As FDA Accepts Geographic Atrophy Candidate Submission Under Priority Review

Why Theriva Biologics Are Trading Higher By Over 76%; Here Are 20 Stocks Moving Premarket